
Recorded on site at the ASGCT 2026 Annual Meeting in Boston, this mini-series introduces listeners to ASGCT members and the work driving progress across the cell and gene therapy field. In each episode, members are invited to share their backgrounds, discuss the current state of the field, and reflect on the value of ASGCT membership. This series of brief, engaging conversations will help listeners get to know the people, perspectives, and ideas shaping the ASGCT community. In this episode, host Ben McLeod of the ASGCT Communications Committee talks with Dylan Bechtle, Director of Regulatory Policy in North America at Johnson & Johnson. Dylan shares how ASGCT membership has been valuable to his career in the regulatory space, both through its community and its resources for staying up to date with the CGT field. Music: 'Origami' by Scott Buckley – released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil

Member Minutes: Mark Deehan, PhD

Member Minutes: Chrissy Green

A CFTR mRNA isoform for the treatment of 3’ CFTR PTC variants with Normand Allaire
Free AI-powered recaps of ASGCT Podcast Network and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.